Ahrens Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ahrens Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$18.1K	Buy	+400	New	+$19.4K	0.01%	482
2022 Q3	–	Sell	-65	Closed	-$4K	–	312
2022 Q2	$4K	Hold	65	–	–	﹤0.01%	792
2022 Q1	$4K	Hold	65	–	–	﹤0.01%	870
2021 Q4	$5K	Buy	+65	New	+$5.68K	﹤0.01%	869
2021 Q1	–	Sell	-1,685	Closed	-$258K	–	217
2020 Q4	$258K	Buy	+1,685	New	+$199K	0.14%	141
2018 Q3	–	Sell	-3,415	Closed	-$201K	–	177
2018 Q2	$201K	Buy	+3,415	New	+$195K	0.08%	154

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ahrens Investment Partners's CRSP Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in CRISPR Therapeutics (CRSP) in Q1 2023: 400 shares worth $18.1K. The stake represents 0.01% of the portfolio and ranks #482 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in CRSP as recently as Q2 2022.

Ahrens Investment Partners first reported a position in CRSP in Q2 2018 and has held it in 6 quarters since. The position peaked at $258K in Q4 2020. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Ahrens Investment Partners held 400 shares of CRISPR Therapeutics worth $18.1K as of Q1 2023.
CRISPR Therapeutics was a new Ahrens Investment Partners position in Q1 2023.
CRISPR Therapeutics made up 0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #482 holding.
Ahrens Investment Partners first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 6 quarters since.
Ahrens Investment Partners's CRISPR Therapeutics position peaked at $258K in Q4 2020.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.